National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency or End-Stage Renal Disease
Information source: University of California, Davis
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Growth Hormone Deficiency
Phase: N/A
Status: Recruiting
Sponsored by: University of California, Davis Official(s) and/or principal investigator(s):
Lavjay Butani, M.D., Principal Investigator, Affiliation: University of California, Davis
Overall contact:
J. Gularte, Phone: (916) 734-7222
Summary
The purpose of this study is to learn whether growth hormone being administered to children
with Chronic Kidney Disease is effective and if it has any side effects.
Clinical Details
Official title: National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)
Study design: Cohort, Prospective
Primary outcome: The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated.
Eligibility
Minimum age: N/A.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney
Disease
Exclusion Criteria:
- Greater than 18 years old
- Not a patient at the UC Davis Medical Center pediatric clinic
Locations and Contacts
J. Gularte, Phone: (916) 734-7222
UC Davis Medical Center, Sacramento, California 95817, United States; Recruiting
Lavjay Butani, MD, Principal Investigator
Additional Information
Starting date: October 2005
Ending date: January 2010
Last updated: February 14, 2008
|
